Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Expression of FGFR1-4 in Malignant Pleural Mesothelioma Tissue and Corresponding Cell Lines and its Relationship to Patient Survival and FGFR Inhibitor Sensitivity.
Vlacic G, Hoda MA, Klikovits T, Sinn K, Gschwandtner E, Mohorcic K, Schelch K, Pirker C, Peter-Vörösmarty B, Brankovic J, Dome B, Laszlo V, Cufer T, Rozman A, Klepetko W, Grasl-Kraupp B, Hegedus B, Berger W, Kern I, Grusch M. Vlacic G, et al. Among authors: schelch k. Cells. 2019 Sep 16;8(9):1091. doi: 10.3390/cells8091091. Cells. 2019. PMID: 31527449 Free PMC article.
Suppression of activin A signals inhibits growth of malignant pleural mesothelioma cells.
Hoda MA, Münzker J, Ghanim B, Schelch K, Klikovits T, Laszlo V, Sahin E, Bedeir A, Lackner A, Dome B, Setinek U, Filipits M, Eisenbauer M, Kenessey I, Török S, Garay T, Hegedus B, Catania A, Taghavi S, Klepetko W, Berger W, Grusch M. Hoda MA, et al. Among authors: schelch k. Br J Cancer. 2012 Dec 4;107(12):1978-86. doi: 10.1038/bjc.2012.519. Epub 2012 Nov 20. Br J Cancer. 2012. PMID: 23169291 Free PMC article.
Fibroblast growth factor receptor inhibition is active against mesothelioma and synergizes with radio- and chemotherapy.
Schelch K, Hoda MA, Klikovits T, Münzker J, Ghanim B, Wagner C, Garay T, Laszlo V, Setinek U, Dome B, Filipits M, Pirker C, Heffeter P, Selzer E, Tovari J, Torok S, Kenessey I, Holzmann K, Grasl-Kraupp B, Marian B, Klepetko W, Berger W, Hegedus B, Grusch M. Schelch K, et al. Am J Respir Crit Care Med. 2014 Oct 1;190(7):763-72. doi: 10.1164/rccm.201404-0658OC. Am J Respir Crit Care Med. 2014. PMID: 25188816
The optogenetic promise for oncology: Episode I.
Ingles-Prieto A, Reichhart E, Schelch K, Janovjak H, Grusch M. Ingles-Prieto A, et al. Among authors: schelch k. Mol Cell Oncol. 2014 Oct 29;1(4):e964045. doi: 10.4161/23723548.2014.964045. eCollection 2014 Oct-Dec. Mol Cell Oncol. 2014. PMID: 27308360 Free PMC article.
Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro.
Hoda MA, Pirker C, Dong Y, Schelch K, Heffeter P, Kryeziu K, van Schoonhoven S, Klikovits T, Laszlo V, Rozsas A, Ozsvar J, Klepetko W, Döme B, Grusch M, Hegedüs B, Berger W. Hoda MA, et al. Among authors: schelch k. Mol Cancer Ther. 2016 Oct;15(10):2357-2369. doi: 10.1158/1535-7163.MCT-15-0846. Epub 2016 Aug 10. Mol Cancer Ther. 2016. PMID: 27512118
Dysregulated Expression of the MicroRNA miR-137 and Its Target YBX1 Contribute to the Invasive Characteristics of Malignant Pleural Mesothelioma.
Johnson TG, Schelch K, Cheng YY, Williams M, Sarun KH, Kirschner MB, Kao S, Linton A, Klebe S, McCaughan BC, Lin RCY, Pirker C, Berger W, Lasham A, van Zandwijk N, Reid G. Johnson TG, et al. Among authors: schelch k. J Thorac Oncol. 2018 Feb;13(2):258-272. doi: 10.1016/j.jtho.2017.10.016. Epub 2017 Nov 4. J Thorac Oncol. 2018. PMID: 29113949 Free article.
42 results